# Profoundd archive — Epstein Files # Bates number: EFTA00506107 # Title: DACART CAPITAL LLC # Dataset: 9 # Pages: 49 # Images: 49 detected # Tags: epstein, doj, dataset-9, image-described # Source PDF: https://profoundd.com/epstein-docs/EFTA00506107/download # Doc viewer: https://profoundd.com/epstein-docs/EFTA00506107 # # Text below is what Profoundd has extracted from the source PDF. # 'ocr-enriched' tag means OCR was applied to scan-only pages. # Image descriptions are AI-generated factual captions (llava:13b). #---------------------------------------------------------------------- === SUMMARY === DACART CAPITAL LLC San Francisco, California: Where Biotechnology Was Born EFTA00506107 ED.Z..ART CAPITAL LLC DaCart Life Science DaCart Cleantech INVEST IN ENDURING INVESTMENT THEMES - HEALTH OF HUMANS HEALTH OF THE PLANET - EFTA00506108 DaCart Investment Charter Focused on funding Humanitarian Projects that are based on breakthrough technologies designed for the benefit of human health, and the health of the planet. DACAR C_APII AL LL, EFTA00506109 Investing in High Technology • Russian wealth === EXTRACTED TEXT === DACART CAPITAL LLC San Francisco, California: Where Biotechnology Was Born EFTA00506107 ED.Z..ART CAPITAL LLC DaCart Life Science DaCart Cleantech INVEST IN ENDURING INVESTMENT THEMES - HEALTH OF HUMANS HEALTH OF THE PLANET - EFTA00506108 DaCart Investment Charter Focused on funding Humanitarian Projects that are based on breakthrough technologies designed for the benefit of human health, and the health of the planet. DACAR C_APII AL LL, EFTA00506109 Investing in High Technology • Russian wealth needs investments in stable economies & access to centers of innovation (Silicon Valley) • European economies remain vulnerable • Investors need diversification • Various economies • Different industries • Mix of risk levels • Demand for life science and cleantech independent from economic growth DACAR C_AF'11 AL LL, EFTA00506110 DaCart Capital $160 - $210M USA Life Science Fund #1 $75M - $100M ■ $75M Institutional ■ 10 Units @ $2.5M/Unit ■ Available/Optional European Life Science Fund #1 $50M - $75M ■ $30M Institutional ■ 8 Units @ $2.5M/Unit ■ Available USA Cleantech Fund #1 (USivt ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DAGAR C_APII AL LL, EFTA00506111 David Carter, Managing Director • 25+ years executive -level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 , 1 IPO • >$500M raised • Vision - Leadership - • Track record I have the ability to aisringuisn "interesting science from a good investment. DACAR I C API JAL LLC7 • r EFTA00506112 The Case for Investment ■ Investment opportunities identified ■ First 4 investments are teed up • Short time & limited capital to profit/liquidity ■ Managing Director's hands-on involvement • Competitive fees - 2%/20% DACARTGAPIIAL LLC, EFTA00506113 The Case for Investment • Biotechnology • Big markets - big valuations • Big need - big pharma • Modern medicine • Clean Technology • Green chemistries - here now • Clean power - next generation batteries/solar are coming DACAR I CAPI IAL LL, EFTA00506114 DAC AR T C: API JAL L LC2, EFTA00506115 Maji Therapeutics Intra-op Post-op (8 months) EDA.GART IAL LLC7 EFTA00506116 Maji Therapeutics Sham Control Mag x4 Mag x40 Treated DACAR I CAPI TAL LLC:. EFTA00506117 Normal Vein Structure E Endothelial cells laminae -5 4M. ••=.• a•In. aNIMP ••=i• aNIMP Lumen Intima c aNIMP MIN• 711.• ,<_•■••• •111.• a<- 110 .Mi• Media •■•• aNIMP MIND 1111Pratm Adventitia DAGART,APITAL LLC, EFTA00506118 Injury to the Vessel During Surgery E,astc lon,ce •• .,,. C 4.1•• --> , aN•P , 4•1I•P .C_________,.'"' .•IM. , , ••••• , >, > csdol-helial cells Adventitio .11.• dr° DAGAR I ,AVIIAL EFTA00506119 Growth factors, cytokines leading to smooth muscle cell proliferation Elastic: laminc: ilINIP _> Endothelial cells 4=D MQ > ilINIP __≤.___; 4WD ________> __________4i-----______41INIP a <-CIMP ,.> C., °o o 0 0o o o Growth factors, cytokines 0 0 0 0 00 00 4IMMID IMP 4IMIP Lumen Intima Adventitia Fibroblasts, fat cells, interstitial matrix DACART CAPITAL LLC7 EFTA00506120 Mechanism of Neointimal Thickening Medial SMC proliferation () 0 00 0 0 0 0 Endothelial cells Growth factors, cit6b%-- oc) 00Lumen Intima Fibroblasts, fat cells, interstitial IMP la Adventitia IDACART CAP' JAL LLC7 EFTA00506121 SMC migration and neointimal lesion development and graft failure Adventitia Fibroblasts, fat cells, interstitial matrix DACART CAP' LLC: EFTA00506122 Delivery of Virus Endothelial cells IMP ONE& $30 B. We already have a significant investor/strategic partners willing to participate, and non-dilutive funding is available. We have experienced scientific and management teams that have successfully done this before. ........ DACAR I ("API I AL LLC7 EFTA00506142 C ncentRx TARGETED BIOTHERAPY DACAR T C 'AL I L c EFTA00506143 ConcentRx O Autologous Blood Activated to Express T-cell targeting tumor antigens NkG2D Oncolytic Agent (vvDD) into T-cells Tumor Blood Vessels T-Cells Ready to Infuse (Day 15) og C Tumor Eradication (4 - 8 hrs) T-cells Target Tumor And Release Agent To Tumor Cell (48 hrs) DAC AR T C API IAL LLC EFTA00506144 ConcentRx A cell-based therapy platform that is fully automated, high throughput, scalable, and lower cost that allows a patient's cells to be activated and propagated at the point of care with specific and optimized therapeutic function. Cell Propagation/Concentration incubator GMP 11.--LorReagents Introduced I_ Cell Activation Incubator ipatient Infusion Preparation Oncolytic agent ntroduced DACARI CIAPI I AL LL, EFTA00506145 ConcentRx Clinical studies (e.g. Dendreon, Juno) have unequivocally shown that combining an appropriate autologous immune cell with an appropriate tumor cell antigen can achieve a demonstrable oncolytic effect in humans. The ConcentRx technology platform further advances the state of the art in autologous immune cell cancer therapies by: • Employing the patient's own enriched, activated T cells as a delivery vehicle to protect the oncolytic agent from the patient's immune system prior to reaching its target. • Highly efficient targeting by employing an abundant and specific tumor cell antigen (NkG2D). • Conferring long term to tumor post therapy • Incorporating simplified, cost-effective, and scalable immunotherapy production at the point of care. DACAR 1 C:API JAL LLC7 EFTA00506146 ConcentRx ■ What Is It? A proprietary technology platform that adds critical therapeutic function to a patient's own cells, and allows the formulation of specific strategies to treat disease with a precision medicine approach. The platform enables simplified, scalable and cost-effective therapeutic production at the point of care. ■ How Does It Work? In the ovarian cancer application, autologous blood cells are drawn from the patient, these cells are activated to express molecules that target tumor antigens (NkG2D). An oncolytic agent (vaccinia virus) is incorporated into the targeting T- cells, the T-cells are injected into the patient, where they then target the tumor cells, release the oncolytic agent into the tumor cells, and eradicate the tumor cells via lysis. ■ Why Is It Important? The technology platform produces oncolytic agents that are highly tumoricidal, and after therapy there is sustained immunity against the cancer type that was Treatea. ine piarrorm nas me potential To Target an Tumor Types, ana IT can conrer sustained immunity to all tumor cells (both bulk tumors and metastatic disease). DACART CAPITAL LLC.L' EFTA00506147 ConcentRx Investment Thesis • Poised to quickly file IND with unprecedented preclinical data in an area of high unmet medical need - ovarian cancer. ▪ Both components of the dual biotherapy (CIK cells, vaccinia virus) have been extensively vetted by the scientific and regulatory community, and have both been FDA approved for human therapy. ▪ Platform technology play in autologous cell-based immune therapy • production of therapy for other partners in the space • joint development deals with companies seeking to develop autologous therapies • own product portfolio ▪ Scientific and managemetR-t team has a proven track record. DAC ART C_ API JAL LLC: EFTA00506148 ConcentRx Broadly enabling technology platform in autologous cell- based immunotherapy. • Next generation cancer immunotherapy • Regenerative medicine for organs & joints • Immune system prophylaxis and restoration $5 M needed to reach $40M enterprise value in 18 months. $25M need to reach $300M enterprise value in 4 years. DACARI CAPI I AL LL, EFTA00506149 Summary • Investment opportunities identified • 4 projects teed up • We are hunting "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successful ly • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506150 Return on Investment Xenogen Jan-98 Series C $14 M Aug-06 Calper acq. $62 M $1.00 18.8% IRR $4.31 Nov-1 1 Perkin Elmer acq. $210 M $1.00 21.1% IRR $14.58 Cobalt Biofuels Mar-07 II ,„„-13 Series B Series E $17M $117M 4)cr1 .UU nn 36.2% IRR4)O& / nn .OO DiNGART C_APIIAL LL, EFTA00506151 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipient of the Eli Lilly Award from the American Society of Microbiology, an American Cancer Society Professorship and an Investigatorship from the Howard Hughes Medical Institute. He is a past president of the American Society for Virology and a past president of the American Society for Microbiology. He is currently a member of the National Science Advisory Board for Biosecurity, and a member of the Board of Directors of CV Therapeutics, and Merck and Company. Robert Dow, BSc MBChB FRCP (Edin) Dr. Dow's current position is as Vice President of Strategic Product Development for PPD, a global Contract Research Organization. Previously, Dr. Dow served as Chief Medical Officer and Senior Vice President of medical affairs at Cell Genesys. He oversaw all clinical, regulatory and medical affairs activities associated with Cell Genesys' product portfolio. Prior to Cell Genesys, he was Chief Executive Officer of Biolitec Pharma Ltd., a U.K.-based biotechnology company, and also previously held senior executive positions with Quantanova and Scotia Holdings, plc. Prior to that, Dr. Dow was head of Global Drug Development with Hoffman-La Roche in Basel, Switzerland and previously was with Syntex Corporation for over 10 years in various senior positions in drug development. Dr. Dow holds a B.Sc. in Medical Science from the University of St. Andrews and his medical qualification, an MBChB degree, from the of Dundee in Scotland. also isFellow of the Royal College of University He Physiciansof Edinburgh and a Fellow of the Faculty of Pharmaceutical Physicians. DACAR I CAPITAL LLC7 EFTA00506152 Advisory Board Pamela R. Contag, Dr. Contag most recently served as Founder and CEO of Cobalt Technologies, Inc. a venture- backed biofuels company, and raised $40M dollars and placed Cobalt in the top 20 clean tech companies in the US in 2008. Prior to Cobalt, she served as Founder and President of Xenogen Corporation from 1995-2006, with an IPO in 2004 and a merger with Caliper Life Sciences in 2006. She has 36 issued patents and over 65 publications in the field of Microbiology and Engineering and she is a founding Board Member of the Startup America Foundation. Howard Pien Mr. Pien most recently served as Chairman of the Board and CEO of Medarex, Inc. from 2007 to its acquisition by Bristol Myers Squibb Company in September 2009. Prior to that, he was a private consultant from 2006 to 2007. Prior to that he served as President and CEO of Chiron Corporation from 2003 to its acquisition by Novartis AG in 2006. Prior to that he served in various executive capacities for GlaxoSmithKline plc (GSK) and its predecessor companies, culminating in his tenure as President of GSK's International Pharmaceuticals business from 2000 to 2003. Prior to joining SmithKline Beecham plc Mr. Pien worked for six years at Abbott Laboratories and for five years at Merck & Co. Mr. Pien is also a director of Vanda Pharmaceuticals and ViroPharma Incorporated. DACAR 1 CAPIIAL LLC EFTA00506153 References • Michael Eisenson - Charlesbank, Managing Partner • Alan Salzman - VantagePoint, Managing Partner • Kevin Hrusovsky - Perkin Elmer, President of Life Sciences & Technology • Dan Junius - Immunogen, CEO • Al Sommers - JHU, Former Dean, School of Public Health • Chris Jones - J Walter Thompson, former CEO 111 • Bill Halter - Lt. Governor, Arkansas DAC .ART C:APITAL EFTA00506154 DACART CAPITAL LLC San Francisco, California: Where Biotechnology Was Born EFTA00506155 === IMAGE DESCRIPTIONS === [Image 1] The image shows a presentation slide with the title "OvationBio" at the top. Below the title, there is a photograph of two chickens, one brown and one black, standing on a dirt ground. To the right of the chickens, there is a circular arrow pointing to a DNA double helix structure, indicating a connection between the chickens and genetics. The slide appears to be part of a presentation, possibly r [Image 2] The image appears to be a slide from a presentation, specifically about "Maji Therapeutics." It features a series of images showing the progression of a treatment on a sample material. The images are arranged in a row, with the top image showing a control sample, the middle image showing a sample treated with Maji Therapeutics, and the bottom image showing a sample treated with a different therape [Image 3] The image appears to be a digital slide or a photograph with text overlay. The slide has a title at the top that reads "D'Artagnan ArtCapit LLC" and a subtitle below it that says "San Francisco, California." The main body of text on the slide states "Where Biotechnology Was Born." The slide also includes a photograph of a cityscape at sunset or sunrise, with the sky transitioning from warm hues ne [Image 4] The image appears to be a digital slide or a photograph with text overlay. The slide has a title at the top that reads "D'Artagnan ArtCapit LLC" and a subtitle below it that says "San Francisco, California." The main body of text on the slide states "Where Biotechnology Was Born." Below this, there is a photograph of a cityscape at sunset or sunrise, with the sky transitioning from warm hues near [Image 5] The image appears to be a slide from a presentation, specifically about "Maji Therapies." The slide contains a series of images and text. The images show different stages of a treatment process, possibly related to skin or tissue repair. The first image at the top left shows a close-up of a skin surface with what looks like a wound or scar. The second image in the middle left shows a similar skin [Image 6] The image appears to be a slide from a presentation, specifically about "Prediction Biomarkers." The slide contains text and a graphic. The text at the top reads "Prediction Biomarkers" and below it, there are bullet points providing information about the topic. The graphic on the right side of the slide shows a diagram of a human head with a focus on the brain, indicating a discussion about the b